Imperial College London
Portrait Picture

ProfessorJustinStebbing

Faculty of Medicine, Department of Surgery & Cancer

Visiting Professor
 
 
 
//

Contact

 

j.stebbing Website CV

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Jin:2021:10.3389/fonc.2021.680804,
author = {Jin, R and Peng, L and Shou, J and Wang, J and Jin, Y and Liang, F and Zhao, J and Wu, M and Li, Q and Zhang, B and Wu, X and Lan, F and Xia, L and Yan, J and Shao, Y and Stebbing, J and Shen, H and Li, W and Xia, Y},
doi = {10.3389/fonc.2021.680804},
journal = {Frontiers in Oncology},
title = {EGFR-mutated squamous cell lung cancer and its association with outcomes},
url = {http://dx.doi.org/10.3389/fonc.2021.680804},
volume = {11},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: The therapeutic efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutant lung squamous cell carcinoma (SCC) patients remains uncertain. Furthermore, the factors underlying the responsiveness have not been fully investigated. We therefore investigated the link between genomic profiles and EGFR-TKI efficacy. Material and Methods: We consecutively enrolled stage IV, EGFR-mutant, and EGFR-TKI-treated patients with SCC. Patients with EGFR wild-type lung SCC and EGFR-mutant lung adenocarcinoma were consecutively enrolled as controls, and next-generation sequencing (NGS) was performed. Results: In total, 28 EGFR-mutant lung SCC, 41 EGFR-mutant lung adenocarcinoma, and 40 EGFR wild-type lung SCC patients were included. Among the patients with EGFR mutations, shorter progression-free survival (PFS) was observed in SCC compared to adenocarcinoma (4.6 vs. 11.0 months, P<0.001). Comparison of the genomic profiles revealed that EGFR-mutant SCC patients had similar mutation characteristics to EGFR-mutant adenocarcinoma patients, but differed from those with EGFR wild-type SCC. Further exploration of EGFR-mutant SCC revealed that mutations in CREBBP (P = 0.005), ZNF217 (P = 0.016), and the Wnt (P = 0.027) pathway were negatively associated with PFS. Mutations in GRM8 (P = 0.025) were associated with improved PFS. Conclusions: EGFR-mutant lung SCC has a worse prognosis than EGFR-mutant adenocarcinoma. Mutations in other genes, such as CREBBP, ZNF217, GRM8, or Wnt that had implications on PFS raise the possibility of understanding mechanisms of resistance to EGFR-TKI in lung SCC, which will aid identification of potential beneficial subgroups of patients with EGFR-mutant SCCs receiving EGFR-TKIs.
AU  - Jin,R
AU  - Peng,L
AU  - Shou,J
AU  - Wang,J
AU  - Jin,Y
AU  - Liang,F
AU  - Zhao,J
AU  - Wu,M
AU  - Li,Q
AU  - Zhang,B
AU  - Wu,X
AU  - Lan,F
AU  - Xia,L
AU  - Yan,J
AU  - Shao,Y
AU  - Stebbing,J
AU  - Shen,H
AU  - Li,W
AU  - Xia,Y
DO  - 10.3389/fonc.2021.680804
PY  - 2021///
SN  - 2234-943X
TI  - EGFR-mutated squamous cell lung cancer and its association with outcomes
T2  - Frontiers in Oncology
UR  - http://dx.doi.org/10.3389/fonc.2021.680804
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34195081
UR  - http://hdl.handle.net/10044/1/90152
VL  - 11
ER  -
Download